Market Place
Sourcing Support
Biostax. & Statera Biopharma reach mutually beneficial dispute settlement
20 Apr 2023 //
GLOBENEWSWIRE
Statera Biopharma Signs Letter of Intent for Merger with Worksite Labs
15 Mar 2023 //
GLOBENEWSWIRE
Statera Biopharma Receives Positive Nasdaq Listing Determination
27 Oct 2022 //
ACCESSWIRE
Statera Files Form 10-Q and Reaches Agreement with Silverback Capital and AVOF
21 Oct 2022 //
ACCESSWIRE
Statera Biopharma Announces Signing of a Binding MOU with Holobeam Technologies
17 Oct 2022 //
ACCESSWIRE
Statera Biopharma Receives Nasdaq Listing Determination
09 Sep 2022 //
ACCESSWIRE
Statera Announces BF Borgers CPA PC as Independent RPAF
14 Jun 2022 //
GLOBENEWSWIRE
Statera Biopharma Receives Notification Letter from Nasdaq in Form 10-Q Filing
23 May 2022 //
GLOBENEWSWIRE
Statera Biopharma and Lay Sciences Intend to Enter Strategic Partnership
13 May 2022 //
GLOBENEWSWIRE
Statera Biopharma and Immune Therapeutics Announce Strategic Agreement
27 Apr 2022 //
GLOBENEWSWIRE
Statera Biopharma receives Nasdaq notice regarding 10-K filing
21 Apr 2022 //
SEEKINGALPHA
Statera Biopharma, Coeptis Announce Strategic Agreement for Entolimod
13 Apr 2022 //
GLOBENEWSWIRE
Statera Biopharma, Inc. Files Form 12b-25
31 Mar 2022 //
GLOBENEWSWIRE
Statera Biopharma to Report Q4 and Full Year 2021 Financial Results
28 Mar 2022 //
GLOBENEWSWIRE
Statera Biopharma Announces Closing of $5.7 Million Underwritten Public Offering
24 Mar 2022 //
GLOBENEWSWIRE
CORRECTION -- Statera Biopharma Announces Proposed Underwritten Public Offering
22 Mar 2022 //
GLOBENEWSWIRE
Statera Biopharma Announces Pricing of $5.7M Underwritten Public Offering
22 Mar 2022 //
GLOBENEWSWIRE
Statera Biopharma Announces Proposed Underwritten Public Offering
21 Mar 2022 //
GLOBENEWSWIRE
Statera Biopharma says Revised Preliminary Revenue and Financial Results
08 Mar 2022 //
GLOBENEWSWIRE
Statera Biopharma Advances Next-Gen Proprietary Compositions
07 Mar 2022 //
GLOBENEWSWIRE
Statera Biopharma Submits Phase 1Trial Protocol to FDA for Long-Haul COVID-19
02 Mar 2022 //
GLOBENEWSWIRE
Statera Biopharma Submits Phase 1 Trial Protocol to FDA for Long-Haul COVID-19
02 Mar 2022 //
GLOBENEWSWIRE
Statera Biopharma Announces Changes to Board of Directors
25 Feb 2022 //
GLOBENEWSWIRE
Statera Biopharma Announces Revenue and Financial Results of Fiscal Year ‘21
22 Feb 2022 //
GLOBENEWSWIRE
Statera Biopharma Bags CIRB Approval of Phase 3 for Pediatric Crohn’s Disease
15 Feb 2022 //
GLOBENEWSWIRE
Statera Biopharma Announces Closing of $2.0 Million Registered Direct Offering
09 Feb 2022 //
GLOBENEWSWIRE
Statera Biopharma Announces Pricing of $2.0 Million Registered Direct Offering
06 Feb 2022 //
GLOBENEWSWIRE
Statera Biopharma Submits Phase 3 Clinical Trial Protocol to FDA for Invg
29 Dec 2021 //
GLOBENEWSWIRE
Statera Biopharma Submits Ph3 Clinical Trial Protocol to FDA for Investigational
29 Dec 2021 //
BIOSPACE
Statera Biopharma Announces First Patient Dosed in Study of STAT-205
20 Dec 2021 //
GLOBENEWSWIRE
Statera Biopharma gets the OK to resume the study of a potential stockpile drug
02 Dec 2021 //
ENDPTS
